The Misfit Toys of Hong Kong Equities: Biotech Ambitions and Delisted Ghosts
Global Report·- The article analyzes various Hong Kong stock assets, arguing that investors must distinguish between active innovative enterprises and stagnant traditional or defunct entities. - It highlights that companies like Everest Medicines and Bioland are actively advancing commercialization and product lines, while SaaS and traditional financial firms face shrinking spaces or lack growth narratives. - It concludes that market participants should direct capital only toward companies with substantive product delivery while abandoning outdated or delisted assets.SUNSHINE INS 2025 Financial Report Overview: Multiple Core Indicators Growth, Life Insurance New Business Value Increased by 48%
Wallstreetcn·- In the low interest rate and asset scarcity environment, Sunshine Insurance's financial performance in 2025 shows a prudent balance between business growth and risk management. - The company reported a net profit of 6.31 billion yuan, up 15.7%, with premium income reaching 150.72 billion yuan, a 17.4% increase, and a 4.3% rise in embedded value to 120.78 billion yuan. - Notably, Sunshine Life's premium income surpassed 100 billion yuan for the first time, driven by strong growth in bank insurance channels, despite Sunshine Property facing challenges in its guarantee insurance sector.